Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PureTech Health ( (GB:PRTC) ) has issued an announcement.
PureTech Health has reported its capital structure as of 28 February 2026, with 257,927,489 issued ordinary shares of one pence each, of which 16,118,451 are held in treasury. This leaves a total of 241,809,038 voting rights, a key figure for investors and other stakeholders monitoring their notifiable holdings under the FCA’s disclosure and transparency regime.
The disclosure helps ensure regulatory compliance and transparency for shareholders who must track changes in their positions relative to reporting thresholds. By clearly setting out its current voting rights base, PureTech provides the market with up-to-date information that can influence ownership reporting, governance considerations and investor decision-making.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £139.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a biotherapeutics company operating a hub-and-spoke model to develop medicines based on validated pharmacology. It focuses on capital-efficient R&D to advance therapeutic candidates addressing significant patient needs, and its approach has already yielded dozens of drug candidates, including three approved by the U.S. FDA, while leveraging external capital structures to create value for shareholders.
Average Trading Volume: 444,314
Technical Sentiment Signal: Strong Sell
Current Market Cap: £296.8M
See more data about PRTC stock on TipRanks’ Stock Analysis page.